Legal & General Group
FBRX

Legal & General Group’s Forte Biosciences FBRX Stock Holding History

Legal & General Group’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40K Buy
+1,880
New +$44.6K ﹤0.01% 2851
2022
Q2 		– Sell
-48
Closed -$2K – 3568
2022
Q1 		$2K Hold
48
– – ﹤0.01% 3548
2021
Q4 		$3K Hold
48
– – ﹤0.01% 3561
2021
Q3 		$4K Hold
48
– – ﹤0.01% 3483
2021
Q2 		$40K Buy
+48
New +$43.3K ﹤0.01% 3022
2020
Q2 		– Sell
-8
Closed -$4K – 3426
2020
Q1 		$4K Sell
8
-4
-33% -$1.56K ﹤0.01% 3283
2019
Q4 		$2K Buy
12
+2
+20% +$453 ﹤0.01% 3362
2019
Q3 		$2K Hold
10
– – ﹤0.01% 3344
2019
Q2 		$24K Hold
10
– – ﹤0.01% 3124
2019
Q1 		$40K Buy
10
+2
+25% +$7.73K ﹤0.01% 2789
2018
Q4 		$24K Hold
8
– – ﹤0.01% 3003
2018
Q3 		$45K Buy
8
+2
+33% +$7.61K ﹤0.01% 2824
2018
Q2 		$21K Sell
6
-2
-25% -$7.32K ﹤0.01% 3171
2018
Q1 		$37K Hold
8
– – ﹤0.01% 2891
2017
Q4 		$32K Buy
8
+5
+167% +$20K ﹤0.01% 3031
2017
Q3 		$16K Hold
3
– – ﹤0.01% 3214
2017
Q2 		$15K Buy
+3
New +$16.9K ﹤0.01% 3257

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Legal & General Group's FBRX Position: Q2 2026 in Review

Legal & General Group opened a new position in Forte Biosciences (FBRX) in Q2 2026: 1,880 shares worth $40K. The stake represents ﹤0.01% of the portfolio and ranks #2851 among its holdings. This is a return to the name: Legal & General Group previously reported a position in FBRX as recently as Q1 2022.

Legal & General Group first reported a position in FBRX in Q2 2017 and has held it in 17 quarters since. The position peaked at $45K in Q3 2018. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Legal & General Group held 1,880 shares of Forte Biosciences worth $40K as of Q2 2026.
  • Forte Biosciences was a new Legal & General Group position in Q2 2026.
  • Forte Biosciences made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2851 holding.
  • Legal & General Group first reported a position in Forte Biosciences in Q2 2017 and has held it in 17 quarters since.
  • Legal & General Group's Forte Biosciences position peaked at $45K in Q3 2018.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.